MD disease refers to muscular dystrophy, a group of more than 30 genetic diseases that cause progressive weakness and degeneration of the muscles used for movement. All forms of MD worsen over time as muscle fibers break down and are replaced by fat and scar tissue. MD is not contagious and cannot be caused by injury or activity.
The most well-known form, Duchenne muscular dystrophy, affects roughly 1 in every 5,000 males between the ages of 5 and 9. But muscular dystrophy is not a single condition. The different types vary widely in when symptoms first appear, which muscles are affected, how quickly the disease progresses, and how long a person can expect to live.
How Muscular Dystrophy Damages Muscles
Healthy muscle cells rely on a protein called dystrophin, which acts like an anchor connecting the internal structure of each muscle fiber to the supportive framework surrounding it. This anchoring system absorbs the stress of everyday movement, protecting the cell each time a muscle contracts and relaxes.
In the most common forms of MD, mutations in the gene responsible for dystrophin either stop the protein from being made at all or produce a shortened, partially functional version. Without enough working dystrophin, muscle cells tear with normal use. The damaged cells weaken and die over time, which is why people with MD gradually lose the ability to move affected muscles. The same process can affect the heart, since cardiac muscle also depends on dystrophin.
Major Types of Muscular Dystrophy
Each type of MD has a distinct pattern of onset, progression, and severity. Here are the most commonly recognized forms:
- Duchenne: Appears between ages 2 and 6, almost exclusively in boys. It causes widespread muscle weakness starting in the pelvis, upper arms, and upper legs, eventually affecting all voluntary muscles. Historically, survival beyond the early 20s was rare, though modern care has extended life expectancy significantly.
- Becker: Symptoms resemble Duchenne but are less severe and progress more slowly, typically appearing in the teenage years or early adulthood. People with Becker MD often survive into middle age. Like Duchenne, it almost always affects males.
- Myotonic: The most common adult-onset form, appearing between ages 20 and 40. It causes weakness in the face, hands, feet, and neck, along with a distinctive inability to relax muscles after use. Progression is slow, sometimes spanning 50 to 60 years.
- Facioscapulohumeral: Begins in childhood or early adulthood, primarily weakening the face, shoulders, and upper arms. It progresses slowly, with occasional periods of rapid worsening. Life span is often many decades after onset.
- Limb-girdle: Onset ranges from late childhood to middle age, targeting the muscles around the shoulders and hips first. Progression is slow, but heart and lung complications are the primary concern over time.
- Congenital: Present from birth, with general muscle weakness and possible joint problems. It progresses slowly but shortens life span.
- Emery-Dreifuss: Appears in childhood to early teens, affecting the shoulders, upper arms, and shins. Joint stiffness is common. Progression is slow, but heart rhythm problems can cause sudden death.
- Distal: Appears between ages 40 and 60, weakening the hands, forearms, and lower legs. It progresses slowly and rarely causes total disability.
- Oculopharyngeal: Appears between ages 40 and 70, affecting the eyelids and throat muscles. Swallowing becomes increasingly difficult, which can lead to severe weight loss over time.
How MD Is Inherited
Duchenne and Becker muscular dystrophy follow an X-linked inheritance pattern, which explains why they overwhelmingly affect boys. Males have one X chromosome and one Y chromosome. If the single X carries a faulty dystrophin gene, there is no backup copy to compensate. Females have two X chromosomes, so a working copy on one can usually make up for a mutation on the other. Women who carry one mutated copy typically show no symptoms but have a 50% chance of passing the mutation to each child. That means each son of a carrier has a 50% chance of having the disease, and each daughter has a 50% chance of becoming a carrier herself.
Other forms of MD follow different inheritance patterns. Some, like certain types of limb-girdle dystrophy, are autosomal recessive, meaning a child must inherit a faulty gene from both parents. Others, like myotonic dystrophy, can be autosomal dominant, where a single copy of the mutated gene from either parent is enough to cause the disease.
Early Signs to Recognize
In Duchenne MD, the earliest and most recognizable signs tend to appear between ages 2 and 6. Children may walk with a wide stance, walk on their toes, and develop an exaggerated curve in the lower back as weakened hip muscles force the body to compensate. A hallmark clue is the tendency to adopt a prone (face-down) position before standing, which typically disappears in unaffected children by age 3.
As the disease progresses, children develop what’s known as Gowers’ sign: they “climb up” their own thighs with their hands to push themselves to a standing position, compensating for weak pelvic and leg muscles. Even in early stages, mild hand pressure against the thigh when standing can signal the beginning of this pattern. Another common early finding is calves that appear unusually large. This isn’t from muscle growth but from muscle tissue being replaced by fat and fibrous tissue.
In adult-onset forms like myotonic or distal MD, early signs are subtler: difficulty releasing a grip, tripping over curbs due to foot weakness, or drooping eyelids.
How MD Is Diagnosed
Diagnosis typically begins with a blood test measuring creatine kinase, an enzyme that leaks out of damaged muscle cells. In someone without a recent injury, unusually high levels of this enzyme point strongly toward a muscle disease. This blood test is often the first step because it’s simple and inexpensive.
Genetic testing confirms the diagnosis by identifying the specific mutation responsible. This step matters because it determines the exact type of MD, which affects prognosis and treatment options. In some cases, doctors use electromyography, where a small needle inserted into a muscle measures its electrical activity during rest and contraction. Abnormal patterns help distinguish muscle diseases from nerve problems, though this test is rarely needed when Duchenne or Becker MD is suspected.
Life Expectancy and How It Has Changed
For the most severe form, Duchenne MD, survival has improved dramatically over the past several decades. People born before 1970 had a median survival age of about 18 years. For those born between 1970 and 1990, that rose to 24 years. For those born after 1990, median life expectancy has reached 28.1 years, with some recent estimates placing it closer to 31.7 years.
Two advances are largely responsible for this shift. Corticosteroids became the standard treatment starting in the 1990s, slowing muscle loss. Around the same time, assisted ventilation became widely available, addressing the respiratory failure that had been the leading cause of death. Improved heart care has also played a role, since the heart muscle weakens alongside skeletal muscles in Duchenne and Becker MD.
For slower-progressing forms like facioscapulohumeral or myotonic dystrophy, life span can extend decades beyond diagnosis, and some forms like distal MD rarely shorten life at all.
Treatment Options Available Now
There is no cure for any form of muscular dystrophy, but treatments can slow progression and improve quality of life. Corticosteroids remain the backbone of Duchenne treatment, helping preserve muscle strength and delay the loss of walking ability. Physical therapy, bracing, and assisted devices help maintain mobility as the disease advances. Ventilatory support, either overnight or full-time, has become standard as respiratory muscles weaken.
In 2024, the FDA expanded approval for the first gene therapy for Duchenne MD. This treatment delivers a gene that produces a shortened version of the dystrophin protein, about one-third the size of the natural protein but functional enough to provide some of the missing structural support. It is given as a single intravenous infusion and is approved for individuals aged 4 and older with a confirmed genetic mutation. Common side effects include nausea, vomiting, fever, and liver injury that requires monitoring. The therapy represents a meaningful step forward, though long-term outcomes are still being tracked.
For other forms of MD, treatment is primarily supportive: managing heart rhythm problems in Emery-Dreifuss, addressing swallowing difficulties in oculopharyngeal, and using ankle or wrist supports in distal forms. Cardiac monitoring is important across several types, since heart involvement is a leading cause of complications in limb-girdle, Emery-Dreifuss, and Duchenne MD alike.